Cerus (NASDAQ:CERS) Shares Pass Above 200-Day Moving Average – Should You Sell?

Cerus Corporation (NASDAQ:CERS)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.56 and traded as high as $2.13. Cerus shares last traded at $2.06, with a volume of 858,664 shares changing hands.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CERS. Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cerus in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $4.00.

Cerus Stock Performance

The company has a quick ratio of 1.29, a current ratio of 1.89 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $395.71 million, a price-to-earnings ratio of -25.75 and a beta of 1.52. The company has a 50-day moving average price of $1.87 and a 200-day moving average price of $1.56.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.02. Cerus had a negative return on equity of 27.58% and a negative net margin of 8.01%.The firm had revenue of $60.24 million during the quarter, compared to analyst estimates of $55.12 million. As a group, equities research analysts forecast that Cerus Corporation will post -0.08 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC raised its stake in shares of Cerus by 152.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 62,854 shares in the last quarter. AQR Capital Management LLC grew its holdings in Cerus by 291.6% during the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after purchasing an additional 1,064,133 shares during the last quarter. Millennium Management LLC raised its position in shares of Cerus by 12.0% in the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock valued at $4,479,000 after purchasing an additional 344,395 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Cerus in the first quarter valued at approximately $32,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Cerus by 112.5% in the first quarter. Acadian Asset Management LLC now owns 1,898,621 shares of the biotechnology company’s stock worth $2,637,000 after buying an additional 1,005,079 shares during the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.